Iradimed opened higher at $86.64, compared with its previous close of $86.58. In the last trading session, the stock traded between $85.07 and $87.46. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Iradimed is now worth
$ 221.81
Giving a profit of
$ 121.81 (121.81%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-1.36 (-1.57%)
Day High
$87.46
Day Low
$85.07
Day Open
$86.64
Prev Close
$86.58
Volume
54,509
1W Return
-3.83%
1M Return
-4.87%
3M Return
-4.23%
6M Return
1.07%
1Y Return
0.69%
Fundamentals
Market Cap ($ Mn)
1,090
PE Ratio
48.64
PB Ratio
10.94
PEG Ratio
1.31
ROE
24.22%
ROCE
27.38%
EPS (TTM)
$0.51
Investment Returns
1 Week
-3.83%
1 Month
-4.87%
3 Months
-4.23%
6 Months
1.07%
9 Months
-17.33%
Financials
Quarterly
All values in $ Mn
20.4
Jun 25
21.2
Sep 25
22.7
Dec 25
22.0
Mar 26
20.5
Jun 26
24.2
Sep 26
Updates
31Jul
iRadimed Q3 adj EPS $0.54-$0.59 beats $0.52 est; sales top $23.65M
iRadimed (NASDAQ: IRMD) reported third-quarter adjusted earnings per share (EPS) guidance of $0.54 to $0.59, surpassing the consensus analyst estimate of $0.52. The company also projected sales of $23.000 million to $24.500 million, exceeding the market expectation of $23.650 million. This dual beat in both profitability and revenue metrics signals robust operational execution and strong demand for its medical device solutions, providing a positive outlook for near-term financial performance.
3mo ago
31Jul
iRadimed raises FY26 adj EPS to $2.09-$2.24, affirms GAAP
iRadimed Corporation revised its FY2026 financial guidance, raising adjusted EPS to $2.09-$2.24 and affirming GAAP EPS at $1.90-$2.05. Sales outlook was also revised upward.
3mo ago
31Jul
Iradimed Q2 Results: Net profit falls 10%, revenue rises 0.5%
Iradimed Corporation delivered flat revenue growth of 0.5% to $20.5 million in Q2 2026, while net income fell 10% to $5.2 million due to margin compression from new product launch costs. The company declared a $0.20 per share dividend and maintained its full-year 2026 revenue guidance of $91.0-96.0 million.
